Wanbury Ltd

Key disclosures

• EDQM approved Wanbury's Rivaroxaban API, supporting EU and CEP markets.
• US FDA DMF clearance obtained for Paroxetine HCl and Metformin HCl.
• ANDA review is ongoing for multiple Wanbury customers.

Financial highlights

• Revenue from operations Rs 165.6 cr; YoY growth 1.5%.
• Other income Rs 0.4 cr.
• EBITDA Rs 16.6 cr; margin 10.0%.
• PAT Rs 3.2 cr; PAT margin 20%.
• Gross profit Rs 86.9 cr; gross margin 52.5%.
• EPS Rs 0.93.

Financing & ownership changes

• Refinancing: Rs 205 cr borrowings from Axis Finance and Poonawalla Fincorp.
• Borrowing cost reduced to below 10% from 1 July 2026.
• Promoter pledge released for 1,42,03,818 shares; 40.65% of paid-up capital.
• Finance costs expected to fall from Q2 FY27.

Regulatory & approvals

• TGA clears Tanuku API site; GMP certificate enables 3 additional APIs to Australia.
• MFDS Korea inspection at Patalganga completed with zero observations; GMP certificate received.
• Filed DMFs for Diphenhydramine HCl (Malaysia, Singapore) and Paroxetine HCl (Korea, Latin America).
• USFDA No DME deficiency letter for Metformin HCl API across multiple ANDAs.
• Certificate of Suitability for Riveroxaban API received (31 July 2026).
• New Andhra API block under validation; commercial scale-up expected to contribute next quarters.

Outlook & near-term expectations

• Inflation-driven margin pressure in Q1; margins expected to recover from Q2 FY27.
• Topline and profitability expected to improve in coming quarters via API scale-up and margin recovery.
• Lower finance costs and operating leverage anticipated to support growth.

Regulatory update

• Wanbury reports no DMF deficiency letters from USFDA for multiple Metformin HCl API‑based ANDAs.
• Wanbury expands opportunities in South Korea by filing a DMF for an additional API.

Regulatory update

• USFDA conducted routine cGMP inspection at Tanuku facility July 13–17, 2026.
• Form 483 issued with six observations; Wanbury to respond within the stipulated time.
• Company will inform exchanges if there is any further update.

Price movement clarification

• Subject: Clarification on Wanbury price movement.
• No new material event beyond disclosures already made to exchanges.
• Price movement is market-driven; no further disclosures required at present.
• Regulation 30 of SEBI LODR referenced; disclosures filed as required.
• Company will continue to disclose all material events in due timelines.

NCD early redemption

• Board approved full early redemption of 12.5% NCDs via circular resolution dated July 15, 2026.
• Debentures are secured, guaranteed, senior, taxable, non-cumulative, unrated, redeemable, principal protected; ISIN INE107F07029.
• Face value Rs 10 lakh per debenture.
• Debentures issued in two tranches on Feb 28, 2025 and Oct 15, 2025.
• Outstanding principal Rs 180 crore against initial Rs 200 crore issue.
• Record date for early redemption: June 20, 2026.
• Early redemption date to be agreed with debenture holders, on or before Feb 28, 2030.
• Maturity date remains Feb 28, 2030.

Target & Acquirer

• Target: Wanbury Limited; Acquirer: Catalyst Trusteeship Ltd (Debenture Trustee), not promoter group.

Transaction Type

• Release of Non-Disposal Undertaking (NDU); mode: release on shares.

Pre-Transaction Holding

• Before: 36,83,488 shares (10.54%).

Post-Transaction Holding

• After: 0 shares (0%).

Transaction Details

• NDU released on 36,83,488 shares July 9, 2026.

Share Capital Context

• Pre/post capital: 34,939,398 shares; diluted: 34,939,398.

Promoter Status

• Promoter group status: No.

Transaction Date

• Date of transaction: July 9, 2026.